-
Product Insights
NewNet Present Value Model: Relmada Therapeutics Inc’s Esmethadone Hydrochloride
Empower your strategies with our Net Present Value Model: Relmada Therapeutics Inc's Esmethadone Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Relmada Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Relmada Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KUR-502 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KUR-502 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KUR-502 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esmethadone Hydrochloride in Liver Failure (Hepatic Insufficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esmethadone Hydrochloride in Liver Failure (Hepatic Insufficiency) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esmethadone Hydrochloride in Liver Failure (Hepatic Insufficiency) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esmethadone Hydrochloride in Renal Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esmethadone Hydrochloride in Renal Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esmethadone Hydrochloride in Renal Failure Drug Details: REL-1017 (D-methadone) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Esmethadone Hydrochloride in Restless Legs Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esmethadone Hydrochloride in Restless Legs Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esmethadone Hydrochloride in Restless Legs Syndrome Drug Details: REL-1017 (D-methadone)...
-
Product Insights
Restless Legs Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Restless Legs Syndrome - Drugs In Development, 2023’, provides an overview of the Restless Legs Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Liver Failure (Hepatic Insufficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Failure (Hepatic Insufficiency) - Drugs In Development, 2023’, provides an overview of the Liver Failure (Hepatic Insufficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...